The purpose of this study is to see how the body's immune system changes after replacing and
adding new anti-HIV drugs to a patient's current anti-HIV therapy. This study will also see
whether adding drugs is safe. Patients who take part in A5136 are also eligible to take part
in 2 substudies. The purpose of substudy A5140s is to see how many latently infected cells
(cells in which the HIV virus survives) are in the lymph node (small, rounded structures that
make disease-fighting cells). Substudy A5155s will be performed to see how many latently
infected cells are in the blood before and after replacing and adding anti-HIV drugs.
ACTG A5136 is a follow-up study to ACTG 315 and ACTG 375, which were designed to examine the
effects of highly active antiretroviral therapy (HAART) in certain HIV-infected patients.
Many HIV-infected patients have undergone long-term anti-HIV therapy and have had the virus
suppressed. However, most of these patients still have problems with their immune systems.
The reason for these problems is unknown. This study may help researchers understand what
causes immune system problems in people who have low levels of HIV in their blood.
Phase:
N/A
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)